TokenPost topic
1 TokenPost story is tagged AscendisPharma. The newest appear first.
Ascendis Pharma reported long-term Phase 3 data showing Yorvipath sustained biochemical control and reduced supplement reliance in hypoparathyroidism patients over 3.5 years.
Jun 15, 2026, 12:26 AM EDT ยท Business
